Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

PRELIMINARY REPORT ON IMIPRAMINE (TOFRÃNIL)

PRELIMINARY REPORT ON IMIPRAMINE (TOFRÃNIL) trials. It is a highly potent drug to be handled with extreme caution and care. Each patient must be seen daily for dosage adjustment and be under constant medical and nursing observations.1. Delay, J., Deniker, P., Ropert, R., Barande, R., and Eurieult, M. : Ann. M#{233}d.-Psyoh., 116: 601, Oct. 1958.2. Perrin,Broussolle, Oct. 1958.J., Lambert, P. A., Balvet, P., and P.: Ann. M#{233}d.-Psych., 116: 602, A. A., andthe highreports( 1-2) potency of thisphenothiazine.Nerv.3. Kurland, & Ment.Dis.,127:Vasconcellos, J.: 378, Oct. 1958.M.D.1(TOFRANIL)E. FELDMAN,Current reports indicate a modest degree of success in the treatment of depressive states with the new energizing compounds (1-5). The clinical similarity of schizophrenic retardation to depressive retardation leads to the speculation that these same compounds might be of some value in theTwenty-three minated prior various reasons: make progress,patients (27%) to the anticipated12 patients-for excessive hyperactivity;were terdate for failure to6 patients-weakness; and weight loss;of schizophrenia(which usually respond adversely to tranquilizer therapy). Eighty-four schizophrenic patients whose clinical states could be characterized as regressed, withdrawn, indifferent, apathetic3 patients-anorexia 1 patient-increased frequency of seizures; 1 patient-furunculosis. The incidence of untoward side effects was 12% and all side effects cleared promptly when medication was discontinued.Many ported of the side effects in other http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Psychiatry American Psychiatric Publishing, Inc (Journal)

PRELIMINARY REPORT ON IMIPRAMINE (TOFRÃNIL)

American Journal of Psychiatry , Volume 115 (12): 1117 – Jun 1, 1959

PRELIMINARY REPORT ON IMIPRAMINE (TOFRÃNIL)

American Journal of Psychiatry , Volume 115 (12): 1117 – Jun 1, 1959

Abstract

trials. It is a highly potent drug to be handled with extreme caution and care. Each patient must be seen daily for dosage adjustment and be under constant medical and nursing observations.1. Delay, J., Deniker, P., Ropert, R., Barande, R., and Eurieult, M. : Ann. M#{233}d.-Psyoh., 116: 601, Oct. 1958.2. Perrin,Broussolle, Oct. 1958.J., Lambert, P. A., Balvet, P., and P.: Ann. M#{233}d.-Psych., 116: 602, A. A., andthe highreports( 1-2) potency of thisphenothiazine.Nerv.3. Kurland, & Ment.Dis.,127:Vasconcellos, J.: 378, Oct. 1958.M.D.1(TOFRANIL)E. FELDMAN,Current reports indicate a modest degree of success in the treatment of depressive states with the new energizing compounds (1-5). The clinical similarity of schizophrenic retardation to depressive retardation leads to the speculation that these same compounds might be of some value in theTwenty-three minated prior various reasons: make progress,patients (27%) to the anticipated12 patients-for excessive hyperactivity;were terdate for failure to6 patients-weakness; and weight loss;of schizophrenia(which usually respond adversely to tranquilizer therapy). Eighty-four schizophrenic patients whose clinical states could be characterized as regressed, withdrawn, indifferent, apathetic3 patients-anorexia 1 patient-increased frequency of seizures; 1 patient-furunculosis. The incidence of untoward side effects was 12% and all side effects cleared promptly when medication was discontinued.Many ported of the side effects in other

Loading next page...
 
/lp/american-psychiatric-publishing-inc-journal/preliminary-report-on-imipramine-tofr-nil-0roaHv9RIj

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Psychiatric Publishing, Inc (Journal)
Copyright
Copyright © American Psychiatric Association. All rights reserved
ISSN
0002-953X
Publisher site
See Article on Publisher Site

Abstract

trials. It is a highly potent drug to be handled with extreme caution and care. Each patient must be seen daily for dosage adjustment and be under constant medical and nursing observations.1. Delay, J., Deniker, P., Ropert, R., Barande, R., and Eurieult, M. : Ann. M#{233}d.-Psyoh., 116: 601, Oct. 1958.2. Perrin,Broussolle, Oct. 1958.J., Lambert, P. A., Balvet, P., and P.: Ann. M#{233}d.-Psych., 116: 602, A. A., andthe highreports( 1-2) potency of thisphenothiazine.Nerv.3. Kurland, & Ment.Dis.,127:Vasconcellos, J.: 378, Oct. 1958.M.D.1(TOFRANIL)E. FELDMAN,Current reports indicate a modest degree of success in the treatment of depressive states with the new energizing compounds (1-5). The clinical similarity of schizophrenic retardation to depressive retardation leads to the speculation that these same compounds might be of some value in theTwenty-three minated prior various reasons: make progress,patients (27%) to the anticipated12 patients-for excessive hyperactivity;were terdate for failure to6 patients-weakness; and weight loss;of schizophrenia(which usually respond adversely to tranquilizer therapy). Eighty-four schizophrenic patients whose clinical states could be characterized as regressed, withdrawn, indifferent, apathetic3 patients-anorexia 1 patient-increased frequency of seizures; 1 patient-furunculosis. The incidence of untoward side effects was 12% and all side effects cleared promptly when medication was discontinued.Many ported of the side effects in other

Journal

American Journal of PsychiatryAmerican Psychiatric Publishing, Inc (Journal)

Published: Jun 1, 1959

There are no references for this article.